23:23 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Patient sample and mouse studies suggest inhibiting IL-18 or NLRP1 could help treat MM. In patient samples, high bone marrow plasma levels of IL-18 correlated with poor overall survival. In two...
19:23 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Gastric cancer Patient sample and mouse studies suggest inhibiting PYCARD or its downstream effector IL-18 could help treat gastric cancer. In tumor samples from patients, levels of PYCARD and IL-18 were higher than in...
07:00 , Mar 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Pneumonia IL-1b; IL-18; NLR family CARD domain containing 4 (NLRC4); caspase-1 (CASP1) Mouse studies suggest inhibiting inflammasome activation could help...
08:00 , Dec 9, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Multiple sclerosis (MS); neurology IL-18 Studies in mice suggest that inhibiting IL-18 signaling could help treat demyelinating diseases such as MS. In a mouse model...